Physicians will now be able to order Myriad Genetics’ MyRisk® Hereditary Cancer Test and view the results of the test directly in Flatiron Health’s cloud-based electronic medical record (EMR) platform, OncoEMR. MyRisk is the first hereditary cancer test to be incorporated into Flatiron’s OncoEMR. Myriad is a genetic testing pioneer, while Flatiron has spearheaded the use of AI and real-world evidence to create software that improves and streamlines cancer patients’ experiences.
Myriad’s MyRisk with RiskScore evaluates 48 genes associated with 11 different hereditary cancers. Notably, it was developed for patients of all ancestries. The integration with OncoEMR allows 4,200 providers at over 800 community-based cancer care locations in Flatiron’s network across the U.S. to conveniently order, receive, and review MyRisk testing results directly through their daily OncoEMR system.
“Our collaboration with Flatiron integrates MyRisk testing with practicing clinicians’ current workflows, potentially enhancing access to and usability of germline testing for more personalized patient care,” said George Daneker Jr., MD, president and chief clinical officer of oncology, Myriad Genetics.
He added: “By making germline testing interoperable with OncoEMR, we aim to simplify the ordering experience for clinicians in Flatiron’s extensive network and provide important health information that may help improve patient care and outcomes. We look forward to expanding the availability of our other genomic testing solutions onto the OncoEMR platform in the future, addressing the needs of even more patients.”
The streamlined, end-to-end workflow for germline testing in OncoEMR, Flatiron says, provides clinicians with access to the results they need at point-of-care, facilitating personalized treatment decisions for patients while reducing administrative burdens and improving turnaround times for results.
“As we continue to advance personalized medicine, the importance of germline testing at the point of care is critical to improving patient outcomes,” said Stephen Speicher, MD, senior medical director, head of clinical oncology and patient safety at Flatiron Health.
“By giving physicians the ability to order Myriad’s MyRisk Hereditary Cancer Test and to view the results directly within OncoEMR, we’re offering clinicians a seamless way to access the information they need to practice precision medicine, facilitating better patient outcomes, more time with patients, and a better care experience for physicians and their patients.”
Myriad is a leading genetic testing and precision medicine company that develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties.
The company has many notable firsts, including: introducing the first genetic test to assess risk of hereditary breast and ovarian cancer (BRACAnalysis); introducing the only personalized breast cancer risk assessment for patients of all ancestries (MyRisk with RiskScores); developing GeneSight, a leading pharmacogenomics test to guide prescriptions for patients with anxiety, depression, and ADHD; and launching Precise Oncology Solutions which combines genetic insights from multiple tests to guide treatment decisions.
Flatiron uses AI, machine learning, and real-world evidence to provide technology and services for patient care. They partner with hundreds of cancer centers, over 20 top global developers of oncology therapeutics, and researchers and regulators around the world.
